Cornerstone Advisors (Washington)’s Supernus Pharmaceuticals SUPN Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$1K	Buy	36 +12	+50%	+$272	﹤0.01%	690
2020 Q2	$1K	Sell	24 -11	-31%	-$243	﹤0.01%	683
2020 Q1	$1K	Buy	+35	New	+$736	﹤0.01%	712
2019 Q3	–	Sell	-813	Closed	-$27K	–	1301
2019 Q2	$27K	Buy	813 +74	+10%	+$2.54K	﹤0.01%	580
2019 Q1	$26K	Sell	739 -14	-2%	-$521	﹤0.01%	545
2018 Q4	$25K	Hold	753	–	–	﹤0.01%	463
2018 Q3	$38K	Hold	753	–	–	0.02%	381
2018 Q2	$45K	Hold	753	–	–	0.03%	327
2018 Q1	$34K	Buy	753 +14	+2%	+$584	0.02%	377
2017 Q4	$29K	Hold	739	–	–	0.02%	406
2017 Q3	$30K	Sell	739 -292	-28%	-$12.6K	0.02%	392
2017 Q2	$44K	Hold	1,031	–	–	0.02%	304
2017 Q1	$32K	Hold	1,031	–	–	0.02%	377
2016 Q4	$26K	Hold	1,031	–	–	0.02%	414
2016 Q3	$25K	Hold	1,031	–	–	0.02%	413
2016 Q2	$21K	Hold	1,031	–	–	0.02%	277
2016 Q1	$16K	Hold	1,031	–	–	0.02%	324
2015 Q4	$14K	Hold	1,031	–	–	0.02%	383
2015 Q3	$14K	Buy	+1,031	New	+$19.2K	0.01%	388

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Cornerstone Advisors (Washington)'s SUPN Position: Q3 2020 in Review

Cornerstone Advisors (Washington) increased its Supernus Pharmaceuticals (SUPN) stake by 50% in Q3 2020, buying an estimated $272 and bringing the position to 36 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #690.

Cornerstone Advisors (Washington) first reported a position in SUPN in Q3 2015 and has held it in 19 quarters since. The position peaked at $45K in Q2 2018. 209 funds tracked by Wall St. Rank hold SUPN as of Q3 2020.

Cornerstone Advisors (Washington) held 36 shares of Supernus Pharmaceuticals worth $1K as of Q3 2020.
Cornerstone Advisors (Washington) bought 12 Supernus Pharmaceuticals shares in Q3 2020, an estimated $272.
Supernus Pharmaceuticals made up ﹤0.01% of Cornerstone Advisors (Washington)'s portfolio in Q3 2020, its #690 holding.
Cornerstone Advisors (Washington) first reported a position in Supernus Pharmaceuticals in Q3 2015 and has held it in 19 quarters since.
Cornerstone Advisors (Washington)'s Supernus Pharmaceuticals position peaked at $45K in Q2 2018.
209 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2020.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2020, filed 20 Oct 2020.